Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient

The development of immunotherapy has recently modified the anti-tumor therapeutic arsenal; particularly, immune checkpoint inhibitors have led to a significant increase in overall survival. The current challenge is now to select good responder patients by identifying early biomarkers to propose ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Milhem, Clara, Moralès, Olivier, Ingelaere, Céline, Pasquier, David, Mordon, Serge, Mortier, Laurent, Mirabel, Xavier, Delhem, Nadira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555181/
https://www.ncbi.nlm.nih.gov/pubmed/32942768
http://dx.doi.org/10.3390/ijms21186772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7555181/
https://www.ncbi.nlm.nih.gov/pubmed/32942768
http://dx.doi.org/10.3390/ijms21186772

Ejemplares similares